ʼһ

XClose

UCL Great Ormond Street Institute of Child Health

Home

Great Ormond Street Institute of Child Health

Menu

Dr Haiyan Zhou

Nucleic Acid Therapeutics for Childhood Genetic Disorders - PI: Haiyan Zhou

The Zhou Lab focuses on developing RNA oligonucleotide therapies for rare childhood disorders, by using the state-of-the-art nucleic acid technology, and to translate these experimental therapies to clinical applications. Our nucleic acid therapy (NAT) programme covers topics on the identification of novel therapeutic targets, design of different RNA therapeutic approaches (ASO, siRNA, microRNA, RNA/gene editing and mRNA), tissue/cell-specific delivery, validation in different model systems (cellular and animal), downstream functional assays and the eventual clinical translation. We have applied this technology to a wide range of genetic disorders and worked closely with UCL colleagues on conditions such as muscular dystrophies (Francesco Muntoni and Jennifer Morgan), respiratory disorders (Hannah Mitchison and Stephen Hart), neurological conditions (Mary Reilly, Manju Kurian, and Amy McTague), inborn errors of metabolism (Paul Gissen, Philippa Mills, Wendy Heywood and Karin Tuschl) and vasculitis (Ying Hong and Despina Eleftheriou).

In addition to the NAT research programme, the Zhou lab has longstanding history in translational research in neuromuscular disorders, including spinal muscular dystrophy, congenital myopathy and muscular dystrophies. Our research interests range from the identification of novel disease mechanisms, therapeutic targets and biomarkers to the development of novel molecular and cellular therapies. For neuromuscular disorders, the Zhou lab works closely with Professor Francesco Muntoni and the Dubowitz Neuromuscular Centre at Great Ormond Street Institute of Child Health.

The Zhou lab is a key training hub for numerous training programmes, including , Marie Skłodowska-Curie Innovative Training Networks PhD fellowship (), China Scholarship Council Training Programme, UCL Child Health Research PhD Programme, and UCL MSc and iBSc research projects.

Main Funding: The Wellcome Trust, UK Research and Innovation, NIHR GOSH BRC, The Royal society, Harrington Discovery Institute, Muscular Dystrophy UK, SMA Europe, UCL Technology Fund, Roche Pharmaceuticals.

Team Members

Project Manager:

  • Catherine Ryan

Senior Research Fellow:

Research Fellows:

  • Dr Charalambos Demetriou*
  • Dr Tomasz Tomkiewicz*
  • *
  • Dr Qiang Zhang

Research Assistants:

  • Sean Briggs
  • Hou Wang Lam*
  • Shunyi Ma
  • Elena Tybulewicz

Clinical Fellow:

  • *

PhD Students:

  • Barbora Cerna*
  • Shuzhi Cheng
  • Fady Guirguis*
  • Parth Patel
  • Kazimir Uzwyshyn-Jones

Visiting staff /Student:

  • Cathy Lin
  • Jannatun Nahar

*Joint supervision

Key references

(A full list of publications can be found at )

  • Lange, J., Zhou, H., & McTague, A. .Front Mol Neurosci. 2022 Jun 27;15:941528
  • Zhou, H..Methods Mol Biol. 2022;2434:53-62.
  • Zaharieva, I. T., Scoto, M., AragonGawinska, K., Ridout, D., Doreste, B., Servais, L., Muntoni, F., Zhou, H..Annals of Clinical and Translational Neurology. 2022 Jul;9(7):1011-1026.
  • Spicer, C., Lu, C. H., Catapano, F., Scoto, M., Zaharieva, I., Malaspina, A., Greensmith, L., Muntoni, F., Zhou, H..Annals of Clinical and Translational Neurology. 2021 Apr;8(4):866-876.
  • Aguti, S., Bolduc, V., Ala, P., Turmaine, M., Bönnemann, C. G., Muntoni, F., & Zhou, H. .Molecular Therapy : Nucleic Acids, 2020; 21, 205-216.
  • Aguti, S., Marrosu, E., Muntoni, F., & Zhou, H..Methods Mol Biol.2020;2176:221-2306
  • Zhou, H., Meng, J., Malerba, A., Catapano, F., Sintusek, P., Jarmin, S., Feng, L., Lu-Nguyen, N., Sun, L., Mariot, V., Dumonceaux, J., Morgan, JE., Gissen, P., Dickson, G., Muntoni, F..J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):768-782.
  • Zhou, H., & Muntoni, F. (2020)..Journal of Cachexia, Sarcopenia and Muscle, jcsm.12608. doi:10.1002/jcsm.12608
  • Bolduc V, Foley AR, Solomon-Degefa H, Sarathy A, Donkervoort S, Hu Y, Chen GS, Sizov K, Nalls M, Zhou H, Aguti S, Cummings BB, Lek M, Tukiainen T, Marshall JL, Regev O, Marek-Yagel D, Sarkozy A, Butterfield RJ, Jou C, Jimenez-Mallebrera C, Li Y, Gartioux C, Mamchaoui K, Allamand V, Gualandi F, Ferlini A, Hanssen E; COL6A1 Intron 11 Study Group, Wilton SD, Lamandé SR, MacArthur DG, Wagener R, Muntoni F, Bönnemann CG. A recurrent COL6A1 pseudoexon insertion causes muscular dystrophy and is effectively targeted by splice-correction therapies. JCI Insight. 2019 Mar 21;4(6):e124403.
  • Zhou, H., & Muntoni, F. Morpholino-Mediated Exon Inclusion for SMA. Methods Mol Biol. 2018;1828:467-477
  • Aguti, S., Malerba, A., & Zhou, H. The progress of AAV-mediated gene therapy in neuromuscular disorders. Expert Opinion on Biological Therapy, 2018;18 (6), 681-693.
  • Sardone, V., Zhou, H., Muntoni, F., Ferlini, A., & Falzarano, M. S. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. Molecules. 2017 Apr 5;22(4):563.